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Abstract  
 
Nemaline myopathy (NM) is a heterogeneous congenital skeletal muscle disease with 
cytoplasmic rod-like structures (nemaline bodies) in muscle tissue.  While weakness in NM is 
related to contractile abnormalities, myofiber smallness is an additional abnormality in NM that 
may be treatable. We evaluated the effects of mRK35 (a myostatin inhibitor developed by Pfizer) 
treatment in the TgACTA1
D286G 
mouse model of NM. mRK35 induced skeletal muscle growth 
that led to significant increases in animal bodyweight, forelimb grip strength and muscle fiber 
force, although it should be noted that animal weight and forelimb grip strength in untreated 
TgACTA1
D286G 
mice was not different from controls. Treatment was also associated with an 
increase in the number of tubular aggregates found in skeletal muscle. These findings suggest 
that myostatin inhibition may be useful in promoting muscle growth and strength in Acta1-
mutant muscle, while also further establishing the relationship between low levels of myostatin 
and tubular aggregate formation. 
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Introduction 
Nemaline myopathies (NM) display a diverse range of clinical phenotypes(1) associated with 
mutations in at least 12 genes (ACTA1, NEB, TPM3, TPM2, TNNT1, CFL2, KBTBD13, KLHL40, 
KLHL41, LMOD3, MYPN and MYO18B)(2-9).  All NM cases display nemaline rods upon 
skeletal muscle biopsy, which are aggregates of alpha-actinin and other sarcomeric proteins(10).  
The abundance, size and distribution of the nemaline rods does not correlate well with disease 
severity(2).  While a variety of primary contractile abnormalities have been identified in NM 
patients and mouse models (11-18), myofiber smallness is another, more nonspecific 
pathological feature seen in many NM cases(19). As myofiber smallness (or insufficient numbers 
of sarcomeres in parallel) may contribute to skeletal muscle weakness in NM, we hypothesized 
that induction of myofiber hypertrophy would be of symptomatic benefit in murine models of 
NM. 
 
We have previously used myostatin inhibition to pharmacologically induce myofiber 
hypertrophy in mice(20-22).  Myostatin binds to (and signals through) the activin type IIB 
receptor (ActRIIB), which downregulates several key processes related to myofiber hypertrophy 
and activates the TGF-β pathway, thereby preventing progression through the cell cycle (23, 24).  
Nonfunctional decoys of ActRIIB can be used to inhibit this negative regulator of myofiber size 
leading to myofiber hypertrophy. In our prior work, we used ActRIIB-mFc, a soluble activin 
type IIB receptor with a murine Fc, to induce myofiber hypertrophy in wild type (WT) mice, in 
two murine models of X-linked myotubular myopathy (XLMTM)(20, 21), and in the 
KI.Acta1
H40Y
 mouse model of NM(22).  While a dramatic and positive impact on skeletal muscle 
growth and function was observed in WT mice in all of these studies, the functional impact of 
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hypertrophy on XLMTM muscle was dramatically limited, possibly by the abnormalities of 
excitation-contraction coupling (ECC) that are also encountered in this disease (25-27).  As 
deficiencies of ECC have not been observed in NM mice (11-15) or patients (16-18), this disease 
may be a more appropriate target in which to test myostatin inhibition therapy.  In our recent 
studies, a trial of ActRIIB-mFc in the KI.Acta1
H40Y 
mouse model of NM, increased lifespan but 
did not impact other measures of muscle strength(22).  Unfortunately, this study did not give a 
clear indication of whether myostatin inhibition would be useful in NM patients, particularly 
since the male KI.Acta1
H40Y 
mice often died from a disease complication (bladder outlet 
obstruction) that is not observed in human NM patients(10).   
 
The current study assesses the effects of myostatin inhibition in a different NM mouse model 
(TgACTA1
D286G
) using a second-generation myostatin inhibitor (anti-myostatin antibody, 
mRK35, Pfizer). mRK35 is a murine anti-myostatin antibody that binds to myostatin and GDF-
11 with high affinity, without interfering with other ligands that signal through the ActRIIB 
receptors.  In doing so, this antibody prevents myostatin binding to ActRIIB receptors thereby 
inhibiting downstream signaling to increase skeletal muscle mass and tetanic force (28) (29). To 
test the impact of mRK35 treatment in NM, TgACTA1
D286G
 and age matched WT C57Bl/6J (WT 
C57) mice were injected once per week with 10 mg/kg mRK35 until 6 months of age.  
TgACTA1
D286G 
mice treated with mRK35 showed an overall increase in bodyweight, skeletal 
muscle mass, myofiber size, forelimb grip strength and extensor digitorum longus (EDL) muscle 
fiber force.  These findings illustrate the potential of myostatin inhibition to promote potentially 
useful muscle growth in the context of Acta1 mutations, although it should be noted that 
forelimb grip strength is not abnormally low in untreated TgACTA1
D286G 
mice.  Additionally, 
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while increased numbers of tubular aggregate structures have been reported in TgACTA1
D286G 
mice (30), treatment with mRK35 produced an additional increase in their number. The 
mechanism responsible for tubular aggregate formation is unclear, but the formation of these 
structures did not appear to prevent treatment-related strength increases in these mice.  
Expression analysis of proteins associated with tubular aggregate formation detected treatment-
associated trends towards an increase in SERCA1 in both mRK35-treated WT and 
TgACTA1
D286G 
mice. Overall, our results demonstrate the capacity for mRK35 to increase 
skeletal muscle strength in the TgACTA1
D286G 
mouse model of NM, although our results should 
be interpreted cautiously as several disease-associated phenotypes did not improve with mRK35 
treatment. 
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Results 
Animal Weight Studies 
Vehicle-treated TgACTA1
D286G
 mice became distinguishable from vehicle-treated WT mice by 5 
weeks of life (WOL) (p<0.0332, Figure 1A).  At 6 WOL, WT mice treated with mRK35 began 
to show significant body weight gains compared to vehicle- treated WT mice (25.7g vs 23.3g, 
p<0.0332).  mRK35-treated TgACTA1
D286G
 mice first showed significant body weight increases 
over vehicle-treated TgACTA1
D286G 
mice at 8 WOL (25.1g vs 22.4g, p<0.0332). These 
significant body weight increases then persisted throughout the course of the study.  
 
Upon dissection of animals at 6 months of life, major skeletal muscles were harvested and 
weighed.  Muscles of vehicle-treated TgACTA1
D286G 
mice that weighed significantly less than 
vehicle-treated WT mice included the diaphragm (79.3mg vs 103.67mg, p<0.05), triceps 
(112.06mg vs. 123.89mg, p<0.05), quadriceps (187.00mg vs 211.53mg, p<0.05), and 
gastrocnemii (125.33mg vs. 168.78mg, p<0.05) (Figure 1B).  Treatment with mRK35 
significantly increased the weights of triceps, quadriceps, and gastrocnemii in both WT and 
TgACTA1
D286G 
mice (p<0.05 for each; Figure 1B).  Weight changes in the EDL muscle will be 
described below in the context of physiological testing.  
 
Behavioral Studies 
Forelimb grip strength, rotarod, running wheel, antigravity hanging performance, open field 
activity, and treadmill performance were used to evaluate skeletal muscle weakness and stamina.  
As forelimb grip strength provides a measure of “burst strength” that might be impacted by 
larger skeletal muscles, it was a particularly interesting endpoint in this study (Figure 1C). 
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Vehicle-treated TgACTA1
D286G
 mice did not have grip strength deficits in comparison to vehicle-
treated WT mice. WT mice treated with mRK35 demonstrated greater grip strength than vehicle-
treated WT mice starting at 9 WOL (p<0.0332).  A similar treatment induced increase in grip 
strength was observed in mRK35-treated TgACTA1
D286G 
mice starting at 7 WOL (p<0.0021). 
Differences between groups fluctuated over the course of the 6 month study but ultimately 
persisted until termination (C57/VEH:C57/mRK35 p<0.0002; C57/VEH:D286G/mRK35 
p<0.0021; D286G/VEH:D286G/mRK35 p<0.0002).   
 
Other behavioral assays did not demonstrate changes due to mRK35 treatment, although deficits 
in specific assays (including running wheel and rotarod) were observed that confirm the disease 
phenotype originally reported in TgACTA1
D286G
 mice(14).  Differences between voluntary 
locomotion in the open field test were significant when the animals were 1 month old 
(C57/VEH:D286G/VEH p<0.0002; C57/VEH:D286G/mRK35 p<0.0001), but were diminished 
by 3 months old and absent by 6 months of age (data not shown).  As previously described (22, 
30) the rotarod and voluntary running wheel assays distinguished WT from TgACTA1
D286G
 mice, 
but performance on these assays did not improve with mRK35 treatment.  For the rotarod 
analyses, the vehicle-treated WT mice remained on the rod significantly longer than both the 
vehicle- and mRK35-treated TgACTA1
D286G 
mice (p<0.0001). However, mRK35-treated WT 
mice had poorer performance than untreated WT mice (p<0.005).  No significant differences 
were observed between TgACTA1
D286G 
treatment groups.  Over seven days of voluntary running 
wheel testing, TgACTA1
D286G 
mice had fewer wheel rotations than WT mice (p<0.0021, Figure 
1D).  Treatment with mRK35 did not affect voluntary running wheel performance of 
TgACTA1
D286G 
mice.  This study also included assays that did not show significant differences 
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between groups with respect to either genotype or treatment, including antigravity hanging or 
treadmill performance assays (data not shown), but these assays were not completed on the full 
set of study animals.   
 
Histopathological Studies 
Histological evaluation of quadriceps and gastrocnemius muscles confirmed the previously 
reported abnormalities in TgACTA1
D286G
 mouse muscle, including the presence of decreased 
fiber size, internally-located nuclei, nemaline rods, and tubular aggregates (Figure 2). While 
myofiber size was decreased in vehicle-treated TgACTA1
D286G
 mice in comparison to vehicle-
treated WT mice, mRK35 treatment increased myofiber size in mice of both genotypes 
(C57/VEH: 2805.4 ± 145.2 µm
2
, C57/mRK: 3998.5 ± 159.8 µm
2
, D286G/VEH: 2261.9 ± 99.4 
µm
2
, D286G/mRK: 3102.8 ± 141.1 µm
2
, Figure 2B; C57/VEH:C57/mRK p<0.0001, C57/VEH: 
D286G/VEH p<0.0332 D286G/VEH: D286G/mRK p<0.0002). Estimations of the proportion of 
type 2b (fast, glycolytic) myofibers in the quadriceps muscle were made for a subset of study 
animals (n=6-9 per group).  While there was extensive variation within groups, there was a 
minor skewing toward slightly increased proportions of type 2B fibers in C57 and 
TgACTA1
D286G
 mice treated with mRK35 (C57/VEH: 80.0+1.1%, C57/mRK: 86.9+2.3%, 
D286G/VEH: 67.5+5.4%, D286G/mRK: 75.8+3.0% type 2B fibers).  There also was a trend 
toward a slightly smaller proportion of glycolytic fibers in the TgACTA1
D286G 
mice in 
comparison to the C57 animals. Prior work using the TgACTA1
D286G 
mouse has shown variable 
differences in the oxidative fiber subpopulations (type 1 and 2A) in some muscles, but variation 
in the type 2B fiber populations have not been reported(30). 
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As tubular aggregates and nemaline rods can both appear red on Gomori trichrome staining(31), 
the presence of tubular aggregates was confirmed by identifying dark blue intracytoplasmic 
inclusions on adenylate deaminase staining, and the presence of nemaline rods was confirmed by 
electron microscopy (Figure 2D).  WT mouse muscles also displayed tubular aggregates in some 
myofibers (Figure 2A,C) in the absence of other pathological abnormalities.  Muscles of 
mRK35-treatedWT mice had a trend toward increased percentages of fibers with tubular 
aggregates (C57/VEH: 28.1 ± 7.2 % of fibers, C57/mRK: 36.2 ± 7.2% of fibers, Figure 2C, 
p=ns) but were otherwise histologically normal.  In contrast, there was a marked increase in 
tubular aggregates in the quadriceps muscles of TgACTA1
D286G
 mice following mRK35 
treatment (D286G/VEH: 12.0 ± 3.8% of fibers, D286G/mRK: 50.7 ± 5.3% of fibers, Figure 2C, 
p<0.0002). Of note, there was also a significant increase in tubular aggregate formation in the 
triceps muscles of treated TgACTA1
D286G
 mice (D286G/VEH: 4.5 ± 0.6% of fibers, 
D286G/mRK: 17.1 ± 2.0% of fibers, data not shown, p<0.0001), confirming their presence in 
muscle groups that would be expected to have contributed to the increase in forelimb grip 
strength. 
 
Physiological Studies 
The functional impact of mRK35 treatment was further assessed via measurement of the absolute 
maximum isometric force of membrane-permeabilized single muscle fibers from the extensor 
digitorum longus (EDL) muscle.  As comparisons of absolute and specific force can be impacted 
by muscle size and myofiber type changes, these features were assessed and compared across 
groups.  The EDL muscle displayed a trend toward higher weights in both WT and 
TgACTA1
D286G 
mice after mRK35 treatment, but this did not reach statistical significance 
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(C57/vehicle = 10.04+0.58mg, C57/mRK35 = 14.62+0.47mg, D286G/vehicle = 9.77+0.48mg, 
D286G/mRK35 = 12.55+0.42mg, p = ns, N= 23-26 muscles per group) (Figure 3A).  
Histological evaluation of myofiber types in the EDL muscle showed similar proportions of slow 
and fast fibers in each treatment group.  ATPase stains at pH 9.4 and immunostaining for myosin 
type 2B identified between 0-2 slow myofibers in each muscle, corresponding to a fairly uniform 
type 2B fiber proportion of 99-100% in the EDL irrespective of genotype or treatment (Figure 
3B).  
 
With respect to the functional characteristics of the EDL muscle, myofibers from vehicle-treated 
TgACTA1
D286G
 mice displayed a significant decrease in absolute maximum isometric force in 
comparison to myofibers from vehicle-treated WT mice,  (C57/VEH: 359.3 ± 33.01 µN, 
D286G/VEH:  223.3 ± 22.2 µN, Figure 3C, p=0.0013). This is in accordance with our previously 
published data (32) (33). Treatment with mRK35 significantly increased absolute force in treated 
mice of both genotypes (C57/VEH: 359.3 ± 33.01 µN, C57/mRK: 512.9 ± 31.1 µN, p=0.0023; 
D286G/VEH:  223.3 ± 22.2 µN, D286G/mRK: 327.6 ± 25.68 µN, p=0.0041).  Similarly, 
TgACTA1
D286G
 mice display significantly lower specific force compared to WT mice, regardless 
of treatment (C57/VEH: 135.9 ± 10.3.5 kPavs. D286G/VEH: 106.7 ± 7.445 kPa, p=0.0252; WT-
mRK vs. D286G-mRK, Figure 3D, p=0.0027). However, mRK35 did not have any significant 
effect on specific force, which is consistent with a gain in force due to increased myofiber size 
rather than intrinsic contractile function(34-36). Thus, our findings indicate that treatment with 
mRK35 increases absolute maximum isometric force in WT and TgACTA1
D286G
 mice due to an increase 
in the amount of muscle available for contraction.   
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Hypertrophic Pathway Studies 
The activation of hypertrophic pathways in WT and TgACTA1
D286G 
mice was investigated using 
western blots to measure protein expression.  Many, phosphorylated and non-phosphorylated 
constituents of the Akt signaling pathway, including AKT, pAKT, P70/S6K, p-P70/S6K, p-rps6, 
ActRIIB, myostatin, and MTOR did not show significant differences with respect to genotype or 
treatment group (Figure 4).   However, expression of rpS6 proteins was significantly greater in 
mRK35-treated WT mice than vehicle-treated WT mice (C57/VEH: 0.7049 ± 0.1476, C57/mRK: 
1.286 ± 0.1739, Figure 4, p=0.0436).  Levels of p-eEF2k in mRK35-treated WT mice were 
significantly greater than in mRK35-treated TgACTA1
D286G
 mice (C57/mRK: 0.03752 ± 
0.004144, D286G/mRK: 0.01597 ± 0.004281, Figure 4, p=0.0111). Additionally, p-4EBP1 
levels in mRK35-treated TgACTA1
D286G
 mice were significantly lower than both mRK35-treated 
WT mice and vehicle-treated TgACTA1
D286G
 mice (C57/mRK: 0.2029 ± 0.02263, 
D286G/VEH:0.1568 ± 0.02761, D286G/mRK: 0.06154 ± 0.01771, Figure 4, p= 0.0027 and 
0.0272, respectively). 
 
Composition of Tubular Aggregates 
Expression of proteins related to tubular aggregate development (either known components of 
tubular aggregates or protein products of genes associated with tubular aggregate myopathies) 
was evaluated in WT and TgACTA1
D286G
 mice using western blot analysis.  No significant 
differences in ORAI1, CASQ, Serca1, Dpagt1, calreticulin, or Stim1 were observed between any 
groups (Figure 5).  mRK35 had no significant effect on tubular aggregate protein expression.   
 
Discussion 
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In this study, we further examined the usefulness of myostatin inhibition therapy for NM using 
mRK35, a second-generation myostatin antibody, in the TgACTA1
D286G 
NM mouse model.  We 
found that administration of mRK35 increased bodyweight, skeletal muscle mass, myofiber size 
and force, and forelimb grip strength, but also increased the formation of tubular aggregate 
structures in TgACTA1
D286G 
mice.  While the results should be interpreted cautiously due to the 
lack of forelimb grip strength weakness in untreated TgACTA1
D286G
 mice, these findings support 
a role for increasing myofiber size as a means for improving skeletal muscle strength in at least 
some NM patients.  As this benefit has been variable in our two studies of myostatin inhibition 
using two different ACTA1-NM models (described below), further study is required to predict the 
usefulness of these agents in human NM patients.   
 
We have previously used ActRIIB-mFc (Acceleron Pharma), a first-generation myostatin 
inhibitor that acts as an ActRIIB receptor decoy, as our myostatin inhibition strategy in two 
studies of XLMTM(20, 21) and one study of NM(22) using mouse models.  These studies 
established a significant capacity of ActRIIB-mFc to increase skeletal muscle size and strength 
in WT mice based on the inhibition of signaling through ActRIIB by myostatin or other ligands 
of this receptor.  In this current study, we evaluated the therapeutic benefit of pharmacologically 
induced myofiber hypertrophy using an anti-myostatin antibody called mRK35 (developed by 
Pfizer, Inc).  mRK35 was designed to selectively inhibit myostatin/GDF-11 signaling without 
affecting signaling by other ActRIIB and BMP receptor ligands (29) to provide a potentially 
more favorable safety profile compare to that reported with an ActRIIB antagonist (37). The 
present study establishes the capacity of mRK35 to increase skeletal muscle size and strength in 
WT mice, similar to the observed effects of ActRIIB-mFc treatment in our prior studies (20-22).  
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Furthermore, mRK35 significantly and persistently improved absolute myofiber force in the 
EDL and forelimb grip strength in TgACTA1
D286G 
mice, exceeding the benefits of myostatin 
inhibition that we observed in our prior studies of XLMTM mice or the KI.Acta1
H40Y
 mouse.  
With respect to their mechanism of action,  mRK35 inhibits only myostatin and GDF-11 
signaling whereas ActRIIB-mFc inhibits signaling induced by a panel of TGFb family members.  
Differences in these therapeutic candidates are unlikely to explain the observed dissimilarity in 
therapeutic efficacy between the two NM mouse models.  It is instead more likely that the 
structural or functional derangement produced by the Acta1 H40Y point mutation is less 
amenable to correction by the addition of skeletal muscle mass, whereas the Acta1 D286G 
mutation is more amenable to correction using this strategy.  However, as myofiber hypertrophy 
induced by cross-breeding KI.Acta1
H40Y
 mice with mice overexpressing FHL1 and IGF-1 did 
improve strength in KI.Acta1
H40Y
 mice(13), it is also possible that hypertrophy could be more 
broadly beneficial in NM if different pathways were used or the intervention occurred earlier in 
development. 
 
It is important to note that the functional increases observed following mRK35 treatment of 
TgACTA1
D286G
 mice were restricted to forelimb grip strength and the absolute maximum 
isometric force of membrane-permeabilized single muscle fibers, and that some phenotypes 
associated with weakness in this model (running wheel performance and rotarod performance) 
did not improve with treatment.  The increases in forelimb grip strength demonstrate that it is 
possible to increase strength in TgACTA1
D286G
 muscle using myostatin inhibition, and this assay 
has been highly useful in documenting treatment-related strength increases in control mice in our 
other myostatin inhibition studies(20, 22, 38) .  As this phenotype is not abnormally weak in 
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untreated TgACTA1
D286G
 mice, however, it should be considered an “increase in strength” rather 
than an “improvement of a disease phenotype”.  With respect to the absolute force measurements 
in the EDL, however, one can observe a phenotype where tissue from TgACTA1
D286G
 mice 
display significant weakness in the untreated state and demonstrate an improvement in the 
context of mRK35 treatment.  These differences are not apparent when the data are expressed as 
specific force (which normalizes data according to muscle size), which is most consistent with a 
treatment benefit that is solely explained by an increase in muscle fiber size.  With respect to the 
lack of treatment-related improvement in rotarod and running wheel performance following 
mRK35 treatment, it is possible that these phenotypes are not well-suited to demonstrate 
improvements following myofiber growth, as no treatment-related benefits using these tests were 
observed in our wild type mice.  In our prior studies of wild type mice, the forelimb grip strength 
test correlated well with myofiber hypertrophy, but other behavioral assays (antigravity hanging 
and open field activity, for instance) either remained unchanged or worsened with anti-myostatin 
therapy(20, 22).  To our knowledge, running wheel and rotarod performance have not been 
studied elsewhere in control or diseased mice, but our data suggest that they may not be ideal 
assays for the detection of hypertrophy-related increases in strength. 
 
Tubular aggregates are inclusions comprised of densely packed tubules that are thought to 
originate from the sarcoplasmic reticulum, SR (39).  Several SR-associated proteins are highly 
expressed in tubular aggregates including sarcoplasmic endoplasmic reticulum Ca
2+
 ATPase 1 
(SERCA1), calsequestrin, sarcalumenin, and RyR1(40). While tubular aggregates are observed 
in non-diseased, inbred male mice in association with increasing age(40, 41), very high levels of 
tubular aggregate formation have been observed in a variety of skeletal muscle diseases known 
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collectively as tubular aggregate myopathy (TAM), and mutations in STIM1 and ORAI1, genes 
that encode proteins involved in calcium regulation, are associated with the development of 
TAM(42, 43). Due to the involvement of multiple proteins and genes related to calcium 
signaling, it is now believed that calcium dyshomeostasis drives the formation of tubular 
aggregates(44). Therefore, we investigated the expression of proteins involved in calcium 
regulation. We did not find any significant differences in the expression of proteins related to 
tubular aggregate formation, indicating that none of these proteins are reliable markers for the 
detection of tubular aggregates.  These findings are curious considering the increased number of 
tubular aggregates seen upon microscopic evaluation.  Perhaps tubular aggregate formation 
occurs from a redistribution of these proteins rather than differences in protein expression levels, 
which would not be detected with a western blot assay.  Additionally, it should be noted that 
tubular aggregates appear in the skeletal muscles of old male mice in almost all mouse strains 
(41), and this study evaluated treatment efficacy in male mice only.  It is unknown whether 
myostatin inhibition affects tubular aggregate formation in female mice.   
 
In comparing this study of mRK35 treatment in TgACTA1
D286G
 mice to our prior studies using 
ActRIIB-mFc in WT, XLMTM, and KI.Acta1
H40Y
 mice, it is also noteworthy that we did not 
encounter tubular aggregates in our studies using ActRIIB-mFc.  The present study identified a 
treatment-associated increase in fibers containing tubular aggregates in TgACTA1
D286G
 mice, but 
not WT mice (Figure 2).  Our prior studies included mice of the C57/BL6 background(21) and 
mice at 6 months of age(21, 22), so mouse background strain and age does not explain the 
increase in tubular aggregates in TgACTA1
D286G
 mice.  It is possible that formation of tubular 
aggregates is an effect of mRK35 treatment in TgACTA1
D286G 
mice that may not be produced 
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when using ActRIIB-mFc.  As tubular aggregates have also been reported in myostatin-knockout 
mice(45), the formation of tubular aggregates may be a consequence of a specific deficiency in 
myostatin.  Additional experiments in larger numbers of WT mice may be useful in more clearly 
defining the promotion of tubular aggregate formation by various myostatin inhibitors.     
 
Western blots were conducted to determine the effect of the TgACTA1
D286G 
mutation on 
hypertrophy signaling and the degree to which mRK35 therapy altered signaling in these 
pathways.  Treatment with mRK35 increased total rpS6 levels in WT mice. However, no 
significant differences in the levels of proteins involved in hypertrophic pathway signaling 
between vehicle-treated WT and TgACTA1
D286G 
mice were observed.  As in our prior studies(21, 
22), it is possible that hypertrophic signaling events were missed at earlier time points and that 
myofiber growth had plateaued by 6 months of life. Abnormalities of hypertrophyd signaling in 
our prior work were clearest in the context of a lack of response to treatment(22), whereas the 
TgACTA1
D286G 
muscles appeared to be fully responsive to treatment in this study and 
hypertrophic pathway activation may not be any different from WT muscle.    
 
Interestingly, mRK35 did not affect myostatin receptor abundance. Our current findings are 
consistent with our previous report that demonstrated myostatin inhibition using ActRIIB-mFc 
resulted in muscle hypertrophy without affecting myostatin receptor expression in the knockout 
mouse model of myotubular myopathy, although it should once again be noted that ActRIIB-
mFc inhibits myostatin less specifically than mRK35(38). In a previous study using the 
KI.Acta1
H40Y
 mouse model, abnormalities in myostatin expression were observed in untreated 
mice, and myostatin inhibition with ActRIIB-mFc upregulated myostatin receptor expression in 
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WT mice and decreased expression in  KI.Acta1
H40Y 
mice (22).  These findings indicate the 
method of myostatin inhibition (antimyostatin-antibody vs. receptor decoy) may have different 
effects on myostatin receptor expression and that mouse strain and disease model affect receptor 
expression following myostatin inhibition.  As noted above, it is also possible that differences in 
myostatin and its receptor would be present at an earlier stage of treatment, but tissue was not 
taken at earlier timepoints to address this possibility.  
 
In summary, we show that administration of an anti-myostatin antibody (mRK35) which binds to 
myostatin and inhibits its signaling activity, increased muscle growth in TgACTA1
D286G 
mice, 
which resulted in significant increases in animal body weight, skeletal muscle weights, myofiber 
size and force, and forelimb grip strength. Additionally, mRK35-treated TgACTA1
D286G
 mice had 
increased numbers of tubular aggregates in skeletal muscle.  Collectively, our findings indicate 
that a more selective myostatin inhibitor may be a therapeutic intervention to increase strength in 
at least a subset of NM, while also further establishing the relationship between low levels of 
myostatin and tubular aggregate formation.  
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Materials and Methods 
Live Animal Studies 
All studies were performed with approval from the IACUC at The Medical College of 
Wisconsin.  Genotyping of the TgACTA1
D286G 
mice was performed as previously described(13).  
Male TgACTA1
D286G 
mice were homozygous for the ACTA1 mutation (30).  Male C57Bl/6J male 
mice were used as the wild type (WT) control. Beginning at 14-17 days of postnatal life, all mice 
were given intraperitoneal injections of mRK35 (Pfizer, New York, NY) once per week at a dose 
of 10 mg/kg, or an equivalent volume of Dulbecco’s phosphate buffered saline (PBS, the vehicle 
used with mRK35)(20). Mice were weighed five days per week during the treatment period, 
beginning when the first injection was given. Once the mice were weaned at three weeks of age, 
forelimb grip strength was measured weekly using a grip strength meter (Columbus Instruments, 
Columbus, OH, USA)(22).  Antigravity hanging performance, open field and treadmill analysis 
were also performed as previously described(22).  As a terminal physiological test, mice were 
placed on a rotarod (IITC Life Sciences, Woodland Hills, CA) and then with voluntary running 
wheels (Coulbourn Instruments, Whitehall, PA) (14, 22) and monitored for wheel count activity 
for seven days. Mice were then euthanized for tissue collection at 6 months of age. 
 
Pathological Evaluation and Tissue Collection 
CO2 euthanasia was used followed by cervical dislocation.  Skin was removed and photographs 
were taken to assess skeletal muscle bulk.  Internal organs, brain, and a variety of skeletal 
muscles (quadriceps, gastrocnemius, triceps, soleus, extensor digitorum longus, diaphragm) were 
removed. The skeletal muscles were weighed, and frozen in liquid nitrogen-cooled isopentane 
and then stored at -80
o
C, whilst the organs were placed in zinc-buffered formalin. 
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Muscle Histology 
Quadriceps, gastrocnemius, and EDL muscle samples were cross sectioned at 8 µm, mounted on 
slides and stained with hematoxylin and eosin (H&E), Gomori trichrome, ATPase at pH 9.4, or 
adenylate deaminase (31) for evaluation using an Olympus BX53 microscope with an Olympus 
DP72 camera and cellSens Standard software (Olympus, Center Valley, PA, USA).  Frozen 8 
µm quadriceps cross sections were also double-stained with rabbit anti-dystrophin antibodies 
(ab15277, Abcam, Cambridge, MA, 1:100) and mouse monoclonal antibodies against myosin 
heavy chain type 2b (clone BF-F3, Developmental Studies Hybridoma Bank (DSHB), Iowa City, 
IA, 1:50) to determine myofiber size and type.  Secondary antibodies used were Alexa Fluor® 
488 conjugated anti-mouse IgM (Sigma Aldrich, St. Louis, MO, 1:400) and Alexa Fluor® 594-
conjugated anti-rabbit IgG (Molecular Probes, Carlsbad, CA, 1:200).   
 
Fiber size was determined in quadriceps muscle samples through measurements of myofiber 
cross sectional area (20, 46).  As in our recent studies(22), quantitation was performed by 
evaluating the type 2b myosin positive (glycolytic) and type 2b myosin negative (oxidative) 
populations on a whole slide scan of one quadriceps muscle from 7 vehicle-treated WT mice, 6 
mRK35-treated WT mice, 6 vehicle-treated TgACTA1
D286G 
mice, and 6 mRK35-treated 
TgACTA1
D286G
. MinFeret diameter was evaluated using an automated technique developed by 
Dr. Lin Yang, as we have previously reported (20, 21).  
 
Single Fiber Functional Studies 
For myofiber force measurements, we treated EDL muscles immediately after dissection with 
Downloaded from https://academic.oup.com/hmg/advance-article-abstract/doi/10.1093/hmg/ddx431/4774327
by KING'S COLLEGE LONDON user
on 05 January 2018
 21
skinning solution (relaxing solution containing glycerol; 50:50 v/v) for 24 hours at 4°C, after 
which they were transferred to -20°C (47). Single muscle fibers were dissected following the 
same procedure as above. They were then individually attached between connectors leading to a 
force transducer (model 400A; Aurora Scientific) and a lever arm system (model 308B; Aurora 
Scientific). Sarcomere length was set to ≈2.50 µm (known to be optimal for force measurement) 
and the temperature to 15°C (33, 48, 49). The absolute maximal isometric force generation was 
calculated as the difference between the total tension in the activating solution and the resting 
tension measured in the same fiber while in the relaxing solution. Specific force was defined as 
absolute force divided by the fiber cross-sectional area (CSA, estimated from the width and 
depth, assuming an elliptical circumference (33, 48, 49)). Relaxing and activating solutions 
contained 4 mM Mg-ATP, 1 mM free Mg
2+
, 20 mM imidazole, 7 mM EGTA, 14.5 mM creatine 
phosphate, and KCl to adjust
 
the ionic strength to 180 mM and pH to 7.0. The
 
concentrations of 
free Ca
2+
 were 10
-9.00
 M (relaxing solution) and 10
-4.50
 M (activating solution).  
 
Organ Histology 
Formalin-fixed organs from 5 animals per treatment group were paraffin embedded at the 
Children’s Hospital of Wisconsin Research Institute Histology Core, as previously described(50, 
51) and stained using H&E.  Organ histology was reviewed by a board certified anatomic- and 
neuro-pathologist to assess for a full range of possible disease- or treatment-related structural 
abnormalities. 
 
Western Blots   
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Whole gastrocnemius muscles were sliced into 8 µm sections using a cryostat and homogenized 
with lysing buffer (EMD Millipore, Temecula, CA) containing protease inhibitor (Roche, Basel, 
Switzerland) and phosphatase inhibitor (Roche Basel, Switzerland).  Western blot procedures 
were performed as previously described(21, 22, 52). Transferred proteins were probed with 
antibodies against various antigens.  Antibodies obtained from Cell Signaling Technologies 
include those for the following antigens: Akt (4691), phospho-Akt (Ser473; 4060), p70-S6K 
(2708), phospho-p70-S6K (Thr421/Ser424; 9204), S6 ribosomal protein (2217), phospho-S6 
ribosomal protein (Ser240/244; 5364), phospho-eEF2k (Ser366; 3691), phospho-4E-BP1 
(Thr37/46; 2855), and MTOR (2983).  Antibodies obtained from Invitrogen included those 
recognizing the following antigens: androgen receptor (AR441), calreticulin (PA3-900), 
calsequestrin (VIIID12, MA3-913), ORAI1 (6D11A11), Rbfox1 (PA5-29074), and STIM1 
(CDN3H4). Antibodies recognizing the following antigens that were obtained from Abcam 
include: ActRIIB (ab76940), Gfpt1 (ab125069), and Dpagt1 (ab117459). Other antibodies used 
for western blot studies recognize: ankyrin (MAB1683, EMD Millipore), GAPDH (G8795, 
Sigma Aldrich), myostatin (MAB788, R&D Systems, Minneapolis, MN), obscurin (ABT160, 
EMD Millipore), and SERCA1 ATPase (MA3-911, Pierce, Rockford, IL). Antibodies were 
visualized using the appropriate species-specific chemiluminescent HRP antibody detection 
reagent (Bio-Rad Laboratories, Hercules, CA). Adequacy of transfer was determined by Ponceau 
S staining.  Quantification of protein levels normalized to GAPDH was performed with Image 
Lab Software (Bio-Rad Laboratories).  Four mice per treatment group were used for analysis.   
 
Statistical Analysis 
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ANOVAs were performed using Prism 7.0 software (Graphpad, Inc.) on animal bodyweight, 
forelimb grip strength, open field activity, antigravity hanging performance, voluntary running 
wheel, and treadmill performance, and average myofiber size. Tukey post-tests were performed 
on all behavioral measures.  For statistical analysis of western blot data, t-tests were used to 
compare protein expression between different genotypes or treatments.  
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Figure Legends 
Figure 1.  Behavioral impact of mRK35 treatment in WT and TgACTA1
D286G 
mice.   (A) 
Total bodyweight of VEH- and mRK35-treated mice. Treatment of WT mice and TgACTA1
D286G
 
with mRK35 produced significant increases in body mass. (B) Individual muscle weights (mg) 
from VEH- and mRK35-treated mice. Treatment of WT mice and TgACTA1
D286G
 with mRK35 
produced significant increases in triceps, quadriceps, and gastrocnemius muscle weights.  (C) 
Forelimb grip force of VEH- and mRK35-treated mice. Treatment of WT mice and 
TgACTA1
D286G
 with mRK35 produced significant increases in forelimb grip strength.  (D) 
Running wheel testing identified clear differences between genotypes over 7 days of testing, but 
no impact of treatment in either WT or TgACTA1
D286G
 mice.  Bars and asterisk denote significant 
(* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001) differences between treatment groups 
with relevant comparisons.   
 
Figure 2. Pathological impact of mRK35 treatment in WT and TgACTA1
D286G
 mice.  
(A) Representative areas of transversely sectioned quadriceps muscle after sectioning and 
staining. Histology reveals decreased myofiber size in TgACTA1
D286G
 mice compared to WT 
controls. Cytoplasmic aggregates were observed on Gomori trichrome and adenylate deaminase 
staining, characteristic of tubular aggregates. (B) Histogram illustrating myofiber size in 
quadricep muscles of VEH- and mRK35-treated WT and TgACTA1
D286G
 mice.  Treatment with 
mRK35 significantly increased myofiber size in WT and TgACTA1
D286G
 mice. (C) Histogram 
illustrating percent of quadriceps muscle cells containing tubular aggregates. Treatment with 
mRK35 markedly increases the percentage of fibers housing tubular aggregates in 
TgACTA1
D286G
 mice. (D) Electron microscopy images of tubular aggregates (yellow arrow) and 
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nemaline bodies (white arrow). Bars and asterisk denote significant (* P ≤ 0.05, ** P ≤ 0.01, *** 
P ≤ 0.001, **** P ≤ 0.0001) differences between treatment groups with relevant comparisons.   
  
 
Figure 3. Fiber force measurements in the EDL muscle following mRK35 treatment in WT 
and TgACTA1
D286G
 mice. (A) Weights of EDL muscles in study animals (two muscles per 
animal).  (B) Representative images using ATPase stains at pH 9.4 on the EDL muscle show 
glycolytic (type 2) fibers in dark brown and oxidative (type 1) fibers in light tan, with 
approximately 99-100% type 2 fibers observed in all samples evaluated (n=3 per group).  (C) 
Absolute maximum isometric force (µN) of membrane-permeabilized single muscle fibers of the 
extensor digitorum longus determined by the difference between total tension in activating 
solution and resting tension.  (D) Specific force (kPa) for muscles in (C), calculated as absolute 
force divided by fiber cross-sectional area. Asterisks denote significant (P < 0.05) differences 
between treatment groups with relevant comparisons.  Error bars indicate standard error of the 
mean (SEM). 
 
Figure 4. Expression of proteins related to myofiber growth following mRK35 treatment in 
WT and TgACTA1
D286G
 mice. (A) Western blots reveal protein expression of growth-associated 
proteins in the gastrocnemius of individual WT or TgACTA1
D286G
 mice.  (B) Quantified protein 
expression (normalized to GAPDH expression) for each growth-associated protein shown in (A).  
Protein extracted from the gastrocnemius muscle of four 27-week old mice per treatment group 
was tested. Asterisks denote significant (P < 0.05) differences between treatment groups with 
Downloaded from https://academic.oup.com/hmg/advance-article-abstract/doi/10.1093/hmg/ddx431/4774327
by KING'S COLLEGE LONDON user
on 05 January 2018
 36
relevant comparisons.  Error bars indicate SEM. ActRIIB, activin type IIB receptor; GAPDH, 
glyceraldenhyde-3-phophate dehydrogenase. 
 
Figure 5. Expression of proteins related to tubular aggregates in vehicle- and MRK-treated 
mice.  (A) Western blots reveal protein expression of tubular aggregate-associated proteins in the 
gastrocnemius of individual WT or TgACTA1
D286G
 mice.  (B) Quantified protein expression 
(normalized to GAPDH expression) for each protein shown in (A).  Protein extracted from the 
gastrocnemius muscle of four 27-week old mice per treatment group was tested. Error bars 
indicated SEM. CASQ, calsequestrin; GAPDH, glyceraldenhyde-3-phophate dehydrogenase. 
  
Downloaded from https://academic.oup.com/hmg/advance-article-abstract/doi/10.1093/hmg/ddx431/4774327
by KING'S COLLEGE LONDON user
on 05 January 2018
 37
Abbreviations 
ActRIIB: activin type IIB receptor 
ECC: excitation-contraction coupling 
GLM: generalized linear models 
NM: nemaline myopathy 
Ns: not significant 
SEM: standard error of the mean 
SERCA1: sarcoplasmic endoplasmic reticulum Ca
2+
 ATPase 1 
SR: sarcoplasmic reticulum 
TAM: tubular aggregate myopathy 
WT: wild-type 
XLMTM: X-linked myotubular myopathy 
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Figure 1.  Behavioral impact of mRK35 treatment in WT and TgACTA1D286G mice.   (A) Total bodyweight of 
VEH- and mRK35-treated mice. Treatment of WT mice and TgACTA1D286G with mRK35 produced significant 
increases in body mass. (B) Individual muscle weights (mg) from VEH- and mRK35-treated mice. Treatment 
of WT mice and TgACTA1D286G with mRK35 produced significant increases in triceps, quadriceps, and 
gastrocnemius muscle weights.  (C) Forelimb grip force of VEH- and mRK35-treated mice. Treatment of WT 
mice and TgACTA1D286G with mRK35 produced significant increases in forelimb grip strength.  (D) Running 
wheel testing identified clear differences between genotypes over 7 days of testing, but no impact of 
treatment in either WT or TgACTA1D286G mice.  Bars and asterisk denote significant (* P ≤ 0.05, ** P ≤ 
0.01, *** P ≤ 0.001, **** P ≤ 0.0001) differences between treatment groups with relevant comparisons.    
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Figure 2. Pathological impact of mRK35 treatment in WT and TgACTA1D286G mice.  
(A) Representative areas of transversely sectioned quadriceps muscle after sectioning and staining. 
Histology reveals decreased myofiber size in TgACTA1D286G mice compared to WT controls. Cytoplasmic 
aggregates were observed on Gomori trichrome and adenylate deaminase staining, characteristic of tubular 
aggregates. (B) Histogram illustrating myofiber size in quadricep muscles of VEH- and mRK35-treated WT 
and TgACTA1D286G mice.  Treatment with mRK35 significantly increased myofiber size in WT and 
TgACTA1D286G mice. (C) Histogram illustrating percent of quadriceps muscle cells containing tubular 
aggregates. Treatment with mRK35 markedly increases the percentage of fibers housing tubular aggregates 
in TgACTA1D286G mice. (D) Electron microscopy images of tubular aggregates (yellow arrow) and nemaline 
bodies (white arrow). Bars and asterisk denote significant (* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P 
≤ 0.0001) differences between treatment groups with relevant comparisons.  
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Figure 3. Fiber force measurements in the EDL muscle following mRK35 treatment in WT and 
TgACTA1D286G mice. (A) Weights of EDL muscles in study animals (two muscles per animal).  (B) 
Representative images using ATPase stains at pH 9.4 on the EDL muscle show glycolytic (type 2) fibers in 
dark brown and oxidative (type 1) fibers in light tan, with approximately 99-100% type 2 fibers observed in 
all samples evaluated (n=3 per group).  (C) Absolute maximum isometric force (µN) of membrane-
permeabilized single muscle fibers of the extensor digitorum longus determined by the difference between 
total tension in activating solution and resting tension.  (D) Specific force (kPa) for muscles in (C), 
calculated as absolute force divided by fiber cross-sectional area. Asterisks denote significant (P < 0.05) 
differences between treatment groups with relevant comparisons.  Error bars indicate standard error of the 
mean (SEM).  
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Figure 4. Expression of proteins related to myofiber growth following mRK35 treatment in WT and 
TgACTA1D286G mice. (A) Western blots reveal protein expression of growth-associated proteins in the 
gastrocnemius of individual WT or TgACTA1D286G mice.  (B) Quantified protein expression (normalized to 
GAPDH expression) for each growth-associated protein shown in (A).  Protein extracted from the 
gastrocnemius muscle of four 27-week old mice per treatment group was tested. Asterisks denote significant 
(P < 0.05) differences between treatment groups with relevant comparisons.  Error bars indicate SEM. 
ActRIIB, activin type IIB receptor; GAPDH, glyceraldenhyde-3-phophate dehydrogenase.  
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Figure 5. Expression of proteins related to tubular aggregates in vehicle- and MRK-treated mice.  (A) 
Western blots reveal protein expression of tubular aggregate-associated proteins in the gastrocnemius of 
individual WT or TgACTA1D286G mice.  (B) Quantified protein expression (normalized to GAPDH expression) 
for each protein shown in (A).  Protein extracted from the gastrocnemius muscle of four 27-week old mice 
per treatment group was tested. Error bars indicated SEM. CASQ, calsequestrin; GAPDH, glyceraldenhyde-3-
phophate dehydrogenase.  
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